|
Exosomal drug formulations
|
1R41CA189517-01
|
$225,000
|
$112,500
|
GUPTA, RAMESH
|
3P BIOTECHNOLOGIES, INC.
|
|
Core Support for Cancer Center
|
3P30CA013330-41S1
|
$75,000
|
$1,500
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
3P30CA013330-41S2
|
$148,500
|
$2,970
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Core Support for Cancer Center
|
5P30CA013330-41
|
$3,585,248
|
$71,705
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Taxol: Mechanisms of Action and Resistance
|
5R01CA077263-14
|
$390,474
|
$390,474
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE
|
|
Bay Area Tumor Institute CCOP
|
3U10CA045461-24S1
|
$81,028
|
$1,621
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
The Role of SRC-1 in Breast Cancer
|
5R01CA112403-08
|
$261,640
|
$65,410
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-29S1
|
$86,403
|
$5,184
|
NICHOLS, CRAIG
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
1K99CA183914-01A1
|
$169,668
|
$169,668
|
WAN, LIXIN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S5
|
$110,177
|
$12,119
|
KACHNIC, LISA
|
BOSTON MEDICAL CENTER
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S1
|
$74,051
|
$1,481
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S2
|
$29,166
|
$583
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-24S3
|
$145,188
|
$2,904
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-24
|
$4,748,649
|
$94,973
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Novel c-Abl-directed Therapies to Alleviate Metastatic Breast Cancer
|
5F31CA180670-02
|
$30,552
|
$10,082
|
MORRISON, CHEVAUN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
c-Abl-mediated Suppression of Breast Cancer Development and Metastasis
|
5R01CA177069-02
|
$318,418
|
$79,605
|
SCHIEMANN, WILLIAM
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Delaware/Christiana Care Community Clinical Oncology Program
|
3U10CA045418-27S1
|
$237,321
|
$4,746
|
GRUBBS, STEPHEN
|
CHRISTIANA CARE HEALTH SERVICES, INC.
|
|
Drug Resistance In Cancer Therapy
|
5R01CA149359-05
|
$384,382
|
$384,382
|
LABHASETWAR, VINOD
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Total Synthesis and Biosynthesis of Bioactive Substances
|
2R01CA070375-18A1
|
$268,515
|
$134,258
|
WILLIAMS, ROBERT
|
COLORADO STATE UNIVERSITY
|
|
Columbia University Medical Center Minority-Based Community Clinical Oncology Pro
|
3U10CA167791-02S1
|
$73,416
|
$1,468
|
KELLY, KARA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Columbus Community Clinical Oncology Program (Columbus CCOP)
|
3U10CA035261-30S1
|
$135,525
|
$8,132
|
KUEBLER, PHILIP
|
COLUMBUS COMMUNITY CLINICAL ONCOLOGY PRG
|
|
Center on the Microenvironment and Metastasis
|
3U54CA143876-05S2
|
$161,591
|
$19,391
|
SHULER, MICHAEL
|
CORNELL UNIVERSITY
|
|
Center on the Microenvironment and Metastasis
|
3U54CA143876-05S3
|
$80,925
|
$9,711
|
SHULER, MICHAEL
|
CORNELL UNIVERSITY
|
|
SPORE: Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
|
5P50CA168504-02
|
$2,162,001
|
$64,860
|
WINER, ERIC
|
DANA-FARBER CANCER INST
|
|
Dayton Clinical Oncology Program
|
3U10CA035090-31S1
|
$166,743
|
$10,005
|
GROSS, HOWARD
|
DAYTON CLINICAL ONCOLOGY PROGRAM
|
|
CENTRAL ILLINOIS COMMUNITY CLINICAL ONCOLOGY PROGRAM
|
3U10CA045807-28S1
|
$240,730
|
$14,444
|
WADE, JAMES
|
DECATUR MEMORIAL HOSPITAL
|
|
Duluth Community Clinical Oncology Program
|
3U10CA035269-30S1
|
$111,679
|
$2,234
|
NIKCEVICH, DANIEL
|
ESSENTIA INSTITUTE OF RURAL HEALTH
|
|
EORTC HEADQUARTERS
|
5U10CA011488-44
|
$155,961
|
$23,394
|
LACOMBE, DENIS
|
EUROPEAN ORG/RES/TREATMENT/CANCER
|
|
North Shore CCOP
|
3U10CA035279-30S1
|
$103,442
|
$6,207
|
VINCIGUERRA, VINCENT
|
FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
|
|
Role of Telmisartan on Intra-Tumoral Distribution of Targeted Nanoparticles
|
1R21CA175618-01A1
|
$182,126
|
$91,063
|
SACHDEVA, MANDIP
|
FLORIDA AGRICULTURAL AND MECHANICAL UNIV
|
|
Community Clinical Oncology Program: FL Pediatric CCOP
|
3U10CA035157-30S1
|
$46,850
|
$937
|
TALBERT, JAMES
|
FLORIDA ASSN OF PEDIATRIC TUMOR PROG
|
|
Geisinger Clinical Oncology Program
|
3U10CA035448-29S2
|
$83,066
|
$1,661
|
GORAK, EDWARD
|
GEISINGER CLINIC
|
|
Greenville SC CCOP
|
3U10CA067663-18S1
|
$152,278
|
$9,137
|
GIGUERE, JEFFREY
|
GREENVILLE HEALTH SYSTEM
|
|
Application of Evolutionary Principles to Maintain Cancer Control (PQ21)
|
5R01CA170595-03
|
$512,520
|
$256,260
|
GATENBY, ROBERT
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
TARGETED INTERVENTION OF BREAST ONCOGENIC PATHWAYS
|
5R01CA098473-10
|
$301,721
|
$75,430
|
SEBTI, SAID
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-16S1
|
$122,584
|
$2,452
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-16S2
|
$75,000
|
$1,500
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
3P30CA076292-16S3
|
$150,000
|
$3,000
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Moffitt Cancer Center Support Grant
|
5P30CA076292-16
|
$2,842,201
|
$56,844
|
SELLERS, THOMAS
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Mechanistic Pharmacology of Anti-Mitotics and Apoptosis Regulation
|
5P01CA139980-05
|
$1,737,021
|
$312,664
|
MITCHISON, TIMOTHY
|
HARVARD MEDICAL SCHOOL
|
|
Hematology-Oncology Associates of Central New York CCOP
|
3U10CA045389-27S1
|
$231,759
|
$13,906
|
KIRSHNER, JEFFREY
|
HEMATOLOGY-ONCOLOGY ASSOCIATES/CTL NY
|
|
Large Scale Synthesis and Biodistribution of Expansile Nanoparticles
|
1R43CA189215-01
|
$224,715
|
$134,829
|
WATHIER, MICHEL
|
IONIC PHARMACEUTICALS
|
|
Iowa Oncology Research Association
|
3U10CA035101-28S1
|
$123,717
|
$2,474
|
BEHRENS, ROBERT
|
IOWA ONCOLOGY RESEARCH ASSOCIATION
|
|
Image-guided combination therapy: noninvasive assessment of delivery and response
|
5R01CA154738-04
|
$550,634
|
$275,317
|
ARTEMOV, DMITRI
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-51S1
|
$75,000
|
$750
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
3P30CA006973-51S3
|
$324,000
|
$3,240
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
Regional Oncology Research Center
|
5P30CA006973-51
|
$6,785,409
|
$67,854
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
TARGETING SPLEEN TYROSINE KINASE IN CHEMORESISTANT OVARIAN CARCINOMA
|
1R21CA187512-01
|
$211,410
|
$211,410
|
WANG, TIAN-LI
|
JOHNS HOPKINS UNIVERSITY
|
|
Kansas City Clincal Oncology Program CCOP
|
3U10CA035176-29S1
|
$97,600
|
$5,856
|
GAUR, RAKESH
|
KANSAS CITY CLINICAL ONCOLOGY PROGRAM
|
|
LSUHSC Minority-Based Community Clinical Oncology Program
|
3U10CA063845-15S1
|
$82,541
|
$1,651
|
VEITH, ROBERT
|
LSU HEALTH SCIENCES CENTER
|
Total relevant funding to Taxol for this search: $18,673,073
|